213 related articles for article (PubMed ID: 18671474)
1. Update on tizanidine for muscle spasticity and emerging indications.
Malanga G; Reiter RD; Garay E
Expert Opin Pharmacother; 2008 Aug; 9(12):2209-15. PubMed ID: 18671474
[TBL] [Abstract][Full Text] [Related]
2. A practical overview of tizanidine use for spasticity secondary to multiple sclerosis, stroke, and spinal cord injury.
Kamen L; Henney HR; Runyan JD
Curr Med Res Opin; 2008 Feb; 24(2):425-39. PubMed ID: 18167175
[TBL] [Abstract][Full Text] [Related]
3. Tizanidine in the management of spasticity and musculoskeletal complaints in the palliative care population.
Smith HS; Barton AE
Am J Hosp Palliat Care; 2000; 17(1):50-8. PubMed ID: 11094920
[TBL] [Abstract][Full Text] [Related]
4. An approach to switching patients from baclofen to tizanidine.
Brenner R; Hyman N; Knobler R; O'Brien M; Stephan T
Hosp Med; 1998 Oct; 59(10):778-82. PubMed ID: 9850294
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of tizanidine in the treatment of spasticity in patients with spinal cord injury. North American Tizanidine Study Group.
Nance PW; Bugaresti J; Shellenberger K; Sheremata W; Martinez-Arizala A
Neurology; 1994 Nov; 44(11 Suppl 9):S44-51; discussion S51-2. PubMed ID: 7970010
[TBL] [Abstract][Full Text] [Related]
6. Open-label dose-titration safety and efficacy study of tizanidine hydrochloride in the treatment of spasticity associated with chronic stroke.
Gelber DA; Good DC; Dromerick A; Sergay S; Richardson M
Stroke; 2001 Aug; 32(8):1841-6. PubMed ID: 11486114
[TBL] [Abstract][Full Text] [Related]
7. Tizanidine for spasticity.
Med Lett Drugs Ther; 1997 Jul; 39(1004):62-3. PubMed ID: 9217694
[No Abstract] [Full Text] [Related]
8. Multi-centre, double-blind trial of a novel antispastic agent, tizanidine, in spasticity associated with multiple sclerosis.
Eyssette M; Rohmer F; Serratrice G; Warter JM; Boisson D
Curr Med Res Opin; 1988; 10(10):699-708. PubMed ID: 3286128
[TBL] [Abstract][Full Text] [Related]
9. A double-blind, placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. United Kingdom Tizanidine Trial Group.
Neurology; 1994 Nov; 44(11 Suppl 9):S70-8. PubMed ID: 7970014
[TBL] [Abstract][Full Text] [Related]
10. Quantification of the effects of an alpha-2 adrenergic agonist on reflex properties in spinal cord injury using a system identification technique.
Mirbagheri MM; Chen D; Rymer WZ
J Neuroeng Rehabil; 2010 Jun; 7():29. PubMed ID: 20573252
[TBL] [Abstract][Full Text] [Related]
11. A double-blind comparative trial of new muscle relaxant, tizanidine (DS 103-282), and baclofen in the treatment of chronic spasticity in multiple sclerosis.
Smolenski C; Muff S; Smolenski-Kautz S
Curr Med Res Opin; 1981; 7(6):374-83. PubMed ID: 7016449
[TBL] [Abstract][Full Text] [Related]
12. Prospective assessment of tizanidine for spasticity due to acquired brain injury.
Meythaler JM; Guin-Renfroe S; Johnson A; Brunner RM
Arch Phys Med Rehabil; 2001 Sep; 82(9):1155-63. PubMed ID: 11552184
[TBL] [Abstract][Full Text] [Related]
13. Nightly sublingual tizanidine HCl in multiple sclerosis: clinical efficacy and safety.
Vakhapova V; Auriel E; Karni A
Clin Neuropharmacol; 2010 May; 33(3):151-4. PubMed ID: 20502134
[TBL] [Abstract][Full Text] [Related]
14. Spasticity: a review.
Young RR
Neurology; 1994 Nov; 44(11 Suppl 9):S12-20. PubMed ID: 7970006
[TBL] [Abstract][Full Text] [Related]
15. Relationship of the antispasticity effect of tizanidine to plasma concentration in patients with multiple sclerosis.
Nance PW; Sheremata WA; Lynch SG; Vollmer T; Hudson S; Francis GS; O'Connor P; Cohen JA; Schapiro RT; Whitham R; Mass MK; Lindsey JW; Shellenberger K
Arch Neurol; 1997 Jun; 54(6):731-6. PubMed ID: 9193208
[TBL] [Abstract][Full Text] [Related]
16. Tizanidine versus baclofen in the treatment of spasticity in multiple sclerosis patients.
Hoogstraten MC; van der Ploeg RJ; vd Burg W; Vreeling A; van Marle S; Minderhoud JM
Acta Neurol Scand; 1988 Mar; 77(3):224-30. PubMed ID: 3376747
[TBL] [Abstract][Full Text] [Related]
17. Optimization of Microemulgel for Tizanidine Hydrochloride.
Jagdale S; Brahmane S; Chabukswar A
Antiinflamm Antiallergy Agents Med Chem; 2020; 19(2):158-179. PubMed ID: 30854978
[TBL] [Abstract][Full Text] [Related]
18. [The usefulness of tizanidine. A one-year follow-up of the treatment of spasticity in infantile cerebral palsy].
Vásquez-Briceño A; Arellano-Saldaña ME; León-Hernández SR; Morales-Osorio MG
Rev Neurol; 2006 Aug 1-15; 43(3):132-6. PubMed ID: 16871477
[TBL] [Abstract][Full Text] [Related]
19. A benefit-risk assessment of baclofen in severe spinal spasticity.
Dario A; Tomei G
Drug Saf; 2004; 27(11):799-818. PubMed ID: 15350152
[TBL] [Abstract][Full Text] [Related]
20. Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders.
Wagstaff AJ; Bryson HM
Drugs; 1997 Mar; 53(3):435-52. PubMed ID: 9074844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]